Outcomes of pediatric patients supported with continuous-flow ventricular assist devices: A report from the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS)

详细信息    查看全文

• 作者：Joseph W. Rossano ; MD^a ; ^{rossanoj@email.chop.edu" class="auth_mail" title="E-mail the corresponding author} ; Angela Lorts ; MD^b ; Christina J. VanderPluym ; MD^c ; Aamir Jeewa ; MD^d ; Kristine J. Guleserian ; MD^e ; Mark S. Bleiweis ; MD^f ; Olaf Reinhartz ; MD^g ; Elizabeth D. Blume ; MD^c ; David N. Rosenthal ; MD^h ; David C. Naftel ; PhDⁱ ; Ryan S. Cantor ; MSPHⁱ ; ^j ; James K. Kirklin ; MDⁱ
• 关键词：pediatric ; ventricular assist devices ; mechanical circulatory support ; heart failure ; outcomes ; bridge to transplant
• 刊名：Journal of Heart and Lung Transplantation
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：35
• 期：5
• 页码：585-590
• 全文大小：720 K

文摘

Continuous-flow (CF) ventricular assist devices (VADs) have largely replaced pulsatile-flow VADs in adult patients. However, there are few data on CF VADs among pediatric patients. In this study we aimed to describe the overall use, patients’ characteristics and outcomes of CF VADs in this population.

c_2">Methods

The Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS) is a national registry for U.S. Food and Drug Adminstration (FDA)-approved VADs in patients <19 years of age. Patients undergoing placement of durable CF VADs between September 2012 and June 2015 were included and outcomes were compared with those of adults from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS).

c_3">Results

CF VADs were implanted in 109 patients at 35 hospitals. The median age at implantation was 15 years (2.8 to 18.9 years) and median weight was 62 kg (range 16 to 141 kg). The underlying disease was cardiomyopathy in 89 (82%) patients. The INTERMACS level at time of implant was Level 1 in 20 (19%), Level 2 in 64 (61%) and Levels 3 to 7 in 21 (20%) patients. Most were implanted as LVADs (n = 102, 94%). Median duration of support was 2.3 months (range <1 day to 28 months). Serious adverse event rates were low, including neurologic dysfunction (early event rate 4.1 per 100 patient-months with 2 late events). Competing outcomes analysis at 6 months post-implant indicated 61% transplanted, 31% alive with device in place and 8% death before transplant. These outcomes compared favorably with the 3,894 adults supported with CF VADs as a bridge to transplant.

c_4">Conclusions

CF VADs are commonly utilized in older children and adolescents, with excellent survival rates. Further study is needed to understand impact of patient and device characteristics on outcomes in pediatric patients.